Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2015
Global Markets Direct’s, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review, H1 2015′, provides an overview of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 6
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 7
Therapeutics Development 8
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies 10
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 17
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance 21
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies 25
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 32
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development 35
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment 108
Drug Profiles 119
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Recent Pipeline Updates 292
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects 340
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products 347
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Product Development Milestones 348
Appendix 355
List of Tables
Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2015 24
Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H1 2015 25
Number of Products under Development by Companies, H1 2015 27
Number of Products under Development by Companies, H1 2015 (Contd..1) 28
Number of Products under Development by Companies, H1 2015 (Contd..2) 29
Number of Products under Development by Companies, H1 2015 (Contd..3) 30
Number of Products under Development by Companies, H1 2015 (Contd..4) 31
Number of Products under Development by Companies, H1 2015 (Contd..5) 32
Number of Products under Investigation by Universities/Institutes, H1 2015 33
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 35
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 36
Comparative Analysis by Late Stage Development, H1 2015 37
Comparative Analysis by Clinical Stage Development, H1 2015 38
Comparative Analysis by Early Stage Development, H1 2015 39
Comparative Analysis by Unknown Stage Development, H1 2015 40
Products under Development by Companies, H1 2015 41
Products under Development by Companies, H1 2015 (Contd..1) 42
Products under Development by Companies, H1 2015 (Contd..2) 43
Products under Development by Companies, H1 2015 (Contd..3) 44
Products under Development by Companies, H1 2015 (Contd..4) 45
Products under Development by Companies, H1 2015 (Contd..5) 46
Products under Development by Companies, H1 2015 (Contd..6) 47
Products under Investigation by Universities/Institutes, H1 2015 48
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 49
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 50
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Absynth Biologics Limited, H1 2015 51
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS, H1 2015 52
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AIMM Therapeutics B.V., H1 2015 53
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Alchemia Limited, H1 2015 54
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Allergan Plc, H1 2015 55
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AlphaMab Co., Ltd, H1 2015 56
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Alvogen, Inc., H1 2015 57
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2015 58
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AnGes MG, Inc., H1 2015 59
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Aphios Corporation, H1 2015 60
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by AstraZeneca Plc, H1 2015 61
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Aurigene Discovery Technologies Limited, H1 2015 62
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Bharat Biotech International Limited, H1 2015 63
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by BioDiem Ltd, H1 2015 64
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by C3 Jian, Inc, H1 2015 65
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Cellceutix Corporation, H1 2015 66
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Cempra, Inc., H1 2015 67
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by ContraFect Corporation, H1 2015 68
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by CrystalGenomics, Inc., H1 2015 69
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC , H1 2015 70
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Debiopharm International S.A., H1 2015 71
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by DesignMedix, Inc., H1 2015 72
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Destiny Pharma Limited, H1 2015 73
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Dong-A Socio Group, H1 2015 74
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Ensoltek Co., Ltd., H1 2015 75
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Excelimmune, Inc., H1 2015 76
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Galapagos NV, H1 2015 77
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by GangaGen Inc., H1 2015 78
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Helix BioMedix, Inc., H1 2015 79
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 80
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Immupharma Plc, H1 2015 81
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by ImmuVen, Inc., H1 2015 82
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc., H1 2015 83
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 84
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015 85
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Lytix Biopharma AS, H1 2015 86
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Madam Therapeutics B.V., H1 2015 87
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 88
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Merck & Co., Inc., H1 2015 89
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Microbiotix, Inc., H1 2015 90
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 91
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by MorphoSys AG, H1 2015 92
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Motif BioSciences, Inc., H1 2015 93
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG, H1 2015 94
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by NanoBio Corporation, H1 2015 95
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 96
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Novabiotics Limited, H1 2015 97
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics, Inc., H1 2015 98
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2015 99
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Novolytics Limited, H1 2015 100
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Oragenics, Inc., H1 2015 101
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Pepscan Presto BV, H1 2015 102
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Pfizer Inc., H1 2015 103
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by PharmaIN Corporation, H1 2015 104
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Phico Therapeutics Limited, H1 2015 105
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Pono Pharma, H1 2015 106
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Procarta Biosystems Ltd, H1 2015 107
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Redx Pharma Plc, H1 2015 108
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015 109
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Savara Inc., H1 2015 110
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH, H1 2015 111
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H1 2015 112
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Soligenix, Inc., H1 2015 113
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics, Inc., H1 2015 114
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Syntiron LLC, H1 2015 115
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co., Ltd., H1 2015 116
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H1 2015 117
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 118
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by United Therapeutics Corporation, H1 2015 119
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Wintermute Biomedical LLC, H1 2015 120
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Wockhardt Limited, H1 2015 121
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by XBiotech USA, Inc., H1 2015 122
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 123
Assessment by Monotherapy Products, H1 2015 124
Assessment by Combination Products, H1 2015 125
Number of Products by Stage and Target, H1 2015 127
Number of Products by Stage and Mechanism of Action, H1 2015 130
Number of Products by Stage and Route of Administration, H1 2015 132
Number of Products by Stage and Molecule Type, H1 2015 134
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics - Recent Pipeline Updates, H1 2015 308
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects, H1 2015 356
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects (Contd..1), H1 2015 357
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects (Contd..2), H1 2015 358
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects (Contd..3), H1 2015 359
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects (Contd..4), H1 2015 360
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects (Contd..5), H1 2015 361
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects (Contd..6), H1 2015 362
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products, H1 2015 363
List of Figures
Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, H1 2015 24
Number of Products under Development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Comparative Analysis, H1 2015 25
Number of Products under Development by Companies, H1 2015 26
Number of Products under Investigation by Universities/Institutes, H1 2015 33
Comparative Analysis by Clinical Stage Development, H1 2015 38
Comparative Analysis by Early Stage Products, H1 2015 39
Assessment by Monotherapy Products, H1 2015 124
Number of Products by Top 10 Targets, H1 2015 126
Number of Products by Stage and Top 10 Targets, H1 2015 126
Number of Products by Top 10 Mechanism of Actions, H1 2015 129
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 129
Number of Products by Top 10 Routes of Administration, H1 2015 131
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 131
Number of Products by Top 10 Molecule Types, H1 2015 133
Number of Products by Stage and Top 10 Molecule Types, H1 2015 133